Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Amylyx Pharma (NASDAQ:AMLX) has been analyzed by 9 analysts, showing a mix of bullish and neutral sentiments with a significant decrease in the average 12-month price target from $27.71 to $9.22, indicating a 66.73% decrease. The company's financial performance shows impressive revenue growth and efficient cost management, with a revenue growth rate of 395.54% and a net margin of 4.36%.
May 10, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amylyx Pharma's stock may face short-term pressure due to the significant decrease in the average 12-month price target by analysts, despite showing strong revenue growth and financial health indicators.
The sharp decrease in the average 12-month price target suggests that analysts have revised their expectations for Amylyx Pharma's stock downwards, which could lead to short-term selling pressure. However, the company's strong revenue growth and financial health might mitigate some negative impacts over time.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100